You are here

AETC ShareSpot: LATITUDE Study to Examine Long-Acting Therapy's Impact

Friday, December 14, 2018

TargetHIV

From the AETC ShareSpot Blog - NIH-supported investigators will launch LATITUDE in 2019, an acronym for Long-Acting Therapy to Improve Treatment Success in Daily Life. The Phase 3 study will compare long-acting HIV antiretroviral therapy regimens to standard therapy in non-adherent individuals.

The LATITUDE study will enroll 350 persons living with HIV as volunteers across 35 clinical research sites in the United States. 

Total views: 127